Thursday, 15 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 2, 2026

GE Aerospace and Grupo Aeroportuario Del Pacifico have been highlighted as Zacks Bull and Bear of the Day

View original at finance.yahoo.com
GE Aerospace and Grupo Aeroportuario Del Pacifico have been highlighted as Zacks Bull and Bear of the Day For Immediate Release Chicago, IL – February 2, 2026 – Zacks Equity Research shares GE Aerospace GE as the Bull of the Day and Grupo Aeroportuario Del Pacífico PAC as the Bear of the Day…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • PAC holds a Zacks Rank #5 (Strong Sell) rating.

    80% confidence
  • Meta plans to complete the rollout of ads in WhatsApp Status throughout 2026.

    80% confidence
  • GE Aerospace's FY26 and FY27 EPS estimates have risen over 6% in the last two months.

    80% confidence
  • GE's balance sheet carries over $12 billion in cash and $130 billion in total assets versus $111 billion in total liabilities.

    80% confidence
  • Meta's GEM model improvements drove a 3.5% lift in ad clicks on Facebook and more than 1% gain in conversions on Instagram in Q4 2025.

    80% confidence
  • GE Aerospace has soared over +280% in the last year and investors may be more inclined to pay a premium after a pullback from an all-time high of $332 a share in early January.

    80% confidence
  • Zacks top stock-picking strategies have achieved average gains of +48.4%, +50.2% and +56.7% per year since 2000 versus the S&P's +7.7% average annual gain.

    80% confidence
  • GE has exceeded the Zacks EPS Consensus for 13 consecutive quarters, posting an average earnings surprise of 14.27% in its last four quarterly reports.

    80% confidence
  • Meta shares climbed 6.6% in the trailing 12 months, underperforming the broader Zacks Computer and Technology sector's return of 27.8%.

    80% confidence
  • GE's total backlog reached roughly $190 billion, up nearly $20 billion year-over-year, with Q4 orders up 74% to $27 billion.

    80% confidence
  • Meta Platforms holds a Zacks Rank #3 (Hold) rating.

    80% confidence
  • Meta, Alphabet, and Amazon are expected to absorb a majority of global ad spending by 2030.

    80% confidence
  • GAP's FY26 sales are projected to slow to a growth rate of 4%.

    80% confidence
  • FY27 EPS projections of $8.55 would reflect 200% growth in five years compared to $2.81 per share in 2021.

    80% confidence
  • The consensus for GE's FY26 EPS has risen above its guidance range to $7.45 compared to $7.15 a week ago.

    80% confidence
  • Meta's advertising revenues in 2025 increased 22.1% from 2024 to $196.18 billion, accounting for 97.6% of total revenues.

    80% confidence
  • GAP's EPS is expected to be up 7% for FY25 and projected to increase another 27% in FY26 to $13.14 per share, but revisions are lower over the last 60 days.

    80% confidence
  • Grupo Aeroportuario Del Pacifico has missed bottom-line expectations for seven consecutive quarters with an average EPS surprise of -6% in its last four quarterly reports.

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com
GE Aerospace and Grupo Aeroportuario Del Pacifico have been highlighted as Zacks Bull and Bear of the Day — Source | Via News | ViaNews EU